|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.5150 - 0.6400|
|52 Week Range||0.3398 - 2.5000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cansortium achieved positive consolidated EBITDA of $1.8 million versus pro-forma EBITDA of $5.8 million in the second quarter of 2018. Consolidated adjusted EBITDA for the quarter was a loss of $2.6 million, compared to adjusted pro-forma positive EBITDA of $100,000 in the same quarter of the previous year. For the first half of 2019, the company reported consolidated revenue of $11.6 million, up by 37% from pro-forma revenue of $8.5 million in the first half of 2018.
Cansortium's focus is on the medical cannabis space in Florida, where it oversees 11 dispensaries and is considered a "large player" in the regulated cannabis market, Burleson said in the Friday initiation note.